Home / Home

Anal Cancer Research

Anal cancer research covers chemoradiation optimization, HPV-driven disease biology, and the emerging role of checkpoint inhibition in advanced squamous cell carcinoma.

Our Anal Cancer Analysis

  • August 5, 2026Clinical Cancer ResearchPOD1UM-303 / POD1UM-202 (NCT04472429; NCT03597295)

    FDA Approves Retifanlimab, First Checkpoint Inhibitor for Anal Squamous Cell Carcinoma

    The FDA approved retifanlimab, a PD-1-targeting checkpoint inhibitor, in combination with carboplatin and paclitaxel for first-line treatment and as a single agent for second-line treatment of squamous cell carcinoma of the anal canal (SCAC) — the first checkpoint inhibitor approval in this disease.